A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19 (TeenCove)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04649151 |
|
Recruitment Status :
Recruiting
First Posted : December 2, 2020
Last Update Posted : May 19, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| SARS-CoV-2 | Biological: mRNA-1273 Biological: Placebo Biological: mRNA-1273.222 | Phase 2 Phase 3 |
This is a Phase 2/3 study, with Part 1A (Blinded Phase), Part 1B (Open-label Observational Phase), Part 1C (Booster Dose (BD) Phase), which consists of Part 1C-1 and Part 1C-2, Part 2 (Open-Label), and Part 3 (Open-label). Participants in Part 1A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part 1B of the study is designed to offer participants whose age group becomes Emergency Use Authorization (EUA) eligible to be unblinded so that participants who received placebo in Part 1A can request 2 doses of open-label mRNA-1273 vaccine. Part 1C-1 of the study will offer participants in Part 1A and Part 1B who are at least 5 months from the last dose, the option to request a homologous BD of mRNA-1273. Part 1C-2 is designed to provide a heterologous BD of mRNA-1273 to eligible participants who completed primary COVID-19 vaccination series with a non-Moderna vaccine under EUA and are at least 3 months from the last dose. Part 2 is an open-label design. Participants will receive 2 doses of mRNA-1273 SARS-CoV-2 vaccine. Part 3 is an open-label design. Participants will receive 2 doses of mRNA-1273.222 vaccine.
Please access http://TeenCoveStudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.
| Study Type : | Interventional |
| Estimated Enrollment : | 4431 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Masking Description: | Part 1A is observer-blind. Participants will remain blinded until the initiation of Part 1B. |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
| Actual Study Start Date : | December 9, 2020 |
| Estimated Primary Completion Date : | August 8, 2024 |
| Estimated Study Completion Date : | March 3, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: mRNA-1273
Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram [ug] each), 28 days apart, on Day 1 and Day 29. Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29. Part 2 (Open-Label): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29. |
Biological: mRNA-1273
Sterile liquid for injection |
|
Placebo Comparator: Placebo
Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
|
Biological: Placebo
0.9% sodium chloride (normal saline) injection |
|
Experimental: mRNA-1273 BD
Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B. Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose. |
Biological: mRNA-1273
Sterile liquid for injection |
|
Experimental: mRNA-1273.222
Part 3 (Open-Label): Participants will receive 2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart, on Day 1 and Day 181.
|
Biological: mRNA-1273.222
Sterile solution for injection |
- Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) [ Time Frame: Up to Day 8 (up to 7 days after each dose) ]
- Number of Participants with Unsolicited Adverse Events (AEs) [ Time Frame: Up to Day 29 (up to 28 days after each dose) ]
- Number of Participants with Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), or Adverse Events of Special Interest (AESI) [ Time Frame: Up to Day 751 ]
- Number of Participants With Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection From COVID-19 [ Time Frame: Day 57 (28 days after second dose) ]Acceptable serum Ab threshold as predefined for the study.
- Geometric Mean (GM) Value of the Serum Ab Level [ Time Frame: Day 57 (28 days after second dose) ]
- Seroresponse Rate (SRR) of Vaccine Recipients [ Time Frame: Day 57 (28 days after second dose) ]
- Number of Participants with AEs Leading to the Discontinuation From Study Post BD [ Time Frame: Up to Day 751 ]
- GM Value of the Serum Ab Level of Original Strain Post BD [ Time Frame: BD-Day 29 ]
- SRR of Vaccine Recipients of Original Strain Post BD [ Time Frame: BD-Day 29 ]
- GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against SARS-CoV-2 Omicron Variant at Day 29 [ Time Frame: Part 3: Day 29 ]
- GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against SARS-CoV-2 Omicron Variant at Day 209 [ Time Frame: Part 3: Day 209 ]
- GM Value of SARS-CoV-2 Spike Protein (S2P)-Specific Binding Antibody (bAb) [ Time Frame: Day 1, Day 57 (1 month after dose 2), Day 209 (6 months after dose 2), and Day 394 (1 year after dose 2) ]
- GM Value of SARS-CoV-2-Specific Neutralizing Antibody (nAb) [ Time Frame: Day 1, Day 57 (1 month after dose 2), Day 209 (6 months after dose 2), and Day 394 (1 year after dose 2) ]
- Number of Participants with a SARS-CoV-2 Infection (Symptomatic or Asymptomatic) Starting 14 Days after the Second Dose of mRNA-1273 or Placebo [ Time Frame: Day 43 up to Day 394 ]Clinical signs indicative of SARS-CoV-2 infection as predefined for the study.
- Number of Participants With Asymptomatic SARS-CoV-2 Infection Measured by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and/or bAb Levels Against SARS-CoV-2 Nucleocapsid Protein [ Time Frame: Day 43 up to Day 394 ]
- Number of Participants with a First Occurrence of Symptomatic COVID-19 Starting 14 days After Second Dose of mRNA-1273 or Placebo [ Time Frame: Day 43 up to Day 394 ]Clinical signs indicative of symptomatic COVID-19 as predefined for the study.
- GM Value of the Serum Ab Level After mRNA-1273 Vaccine Administration Against Circulating Strain [ Time Frame: Part 1C1 and Part 1C2: Day 29 ]
- SRR After mRNA-1273 Vaccine Administration Against Circulating Strain [ Time Frame: Part 1C1 and Part 1C2: Day 29 ]
- GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against Original Strain [ Time Frame: Part 3: Days 29 and 209 ]
- SRR After mRNA-1273.222 Vaccine Administration Against Omicron Variant [ Time Frame: Part 3: Days 29 and 209 ]
- GM Value of the Serum Ab Level After mRNA-1273.222 Vaccine Administration Against Other Variants of Interest [ Time Frame: Part 3: Days 29 and 209 ]
- SRR After mRNA-1273.222 Vaccine Administration Against Original Strain [ Time Frame: Part 3: Days 29 and 209 ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 12 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
For Part 1A, Part 2 and Part 3:
- Participants 12 to <18 years of age at the time of consent (Screening Visit, Day 0) who, in the opinion of the Investigator, are in good general health based on review of medical history and screening physical examination.
- Investigator assessment that the participant, in the case of an emancipated minor, or parent(s)/legally acceptable representative(s) [LAR(s)] understand and is willing and physically able to comply with protocol-mandated follow up, including all procedures and provides written informed consent/assent.
- Body mass index (BMI) at or above the third percentile according to World Health Organization (WHO) Child Growth Standards at the Screening Visit (Day 0)
- Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as premenarche or surgically sterile (history of bilateral tubal ligation, bilateral oophorectomy, hysterectomy).
- Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test at Screening (Day 0), on the day of the first injection (Day 1), on the day of the second injection (Day 29 in Parts 1A and 1B and Part 2, and Day 181 in Part 3); has practiced adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1); and has agreed to continue adequate contraception through 3 months following the second injection (Day 29 in Part 1A and Part 2, and Day 181 in Part 3).
For Part 1C-1 Homologous Booster Dose:
- Participants must have been previously enrolled in the mRNA-1273-P203 study, are actively participating in Part 1A or Part 1B and are least 5 months from the last dose.
- Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (BD-Day 1).
Part 1C-2 Heterologous Booster Dose:
- Male or female, 12 to < 18 years of age at the time of consent who, in the opinion of the investigator, is in good general health based on review of medical history and screening physical examination AND has completed non-Moderna primary COVID-19 vaccination series under EUA (for example, Pfizer) at least 3 months from consent.
Exclusion Criteria:
For Part 1A, Part 2, and Part 3:
- Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of investigational product (IP) or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection of COVID-19 within 2 weeks prior to administration of IP (Part 2 participants only). For Part 3 participants, known history of SARS-CoV-2 infection within 90 days prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID-19 within 90 days prior to administration of IP.
- Travel outside of the United States or home country (Part 2 and Part 3 only) in the 28 days prior to the Screening Visit (Day 0).
- Pregnant or breastfeeding
- Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥38.0°Celsius (C)/≥100.4°Farenheit (F). Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the Investigator.
- Prior administration of an investigational coronavirus (for example, SARS-CoV-2, SARS-CoV, Middle East Respiratory Syndrome [MERS-CoV]) vaccine
- Current treatment with investigational agents for prophylaxis against COVID-19
- Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the Investigator's judgment
- Current use of any inhaled substance (for example, tobacco or cannabis smoke, nicotine vapors)
- History of chronic smoking (≥1 cigarette a day) within 1 year of the Screening Visit (Day 0)
- History of illegal substance use or alcohol abuse within the past 2 years. This exclusion does not apply to historical cannabis use that was formerly illegal in the participant's state but is legal at the time of screening.
-
History of a diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically:
- Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection
- Suspected active hepatitis
- Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy
- Dermatologic conditions that could affect local solicited AR assessments
- History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine
- Diagnosis of malignancy within the previous 10 years (excluding nonmelanoma skin cancer)
- Febrile seizures
-
Receipt of:
- Any licensed vaccine within 28 days before the first dose (Day 1) or plans for receipt of any licensed vaccine through 28 days following any study injection
- Systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥20 mg/day prednisone equivalent). Topical tacrolimus is allowed if not used within 14 days prior to the day of enrollment. Participants may have visits rescheduled for enrollment if they no longer meet this criterion within the Screening Visit window. Inhaled, nasal, and topical steroids are allowed.
- Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment
- Has donated ≥450 mL of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study
- Participated in an interventional clinical study within 28 days prior to the Screening Visit (Day 0) or plans to do so while participating in this study
- Is an immediate family member or has a household contact who is an employee of the research center or otherwise involved with the conduct of the study
-
History of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically:
- Congenital or acquired immunodeficiency, including human immunodeficiency virus (HIV) infection.
- Suspected active hepatitis
- Has a bleeding disorder that is considered a contraindication to IM injection orphlebotomy
- Dermatologic conditions that could affect local solicited AR assessments
- History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine
- Diagnosis of malignancy within the previous 10 years (excluding nonmelanoma skin cancer)
- Febrile seizures
For Part 1B:
- Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (Open-Label-Day 1) and on the day of the second injection (Open-Label-Day 29).
For Part 1C-1 and Part 1C-2:
- Pregnant or breastfeeding.
- Is acutely ill or febrile 24 hours prior to or at the Screening Visit (Day 0). Fever is defined as a body temperature ≥ 38.0°C/≥ 100.4°F. Participants who meet this criterion may have visits rescheduled within the relevant study visit windows. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
- Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
-
History of a diagnosis or condition (after enrolment in Part 1A for potential participants in Part 1C-1) that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety:
- Suspected active hepatitis
- Has a bleeding disorder that is considered a contraindication to IM injection or phlebotomy
- Dermatologic conditions that could affect local solicited AR assessments
- History of anaphylaxis, urticaria, or other significant AR requiring medical intervention after receipt of a vaccine
- Diagnosis of malignancy (excluding nonmelanoma skin cancer)
-
Receipt of:
• Any authorized or licensed vaccine within 28 days before the first dose of investigational product (IP) or plans (COVID-19 vaccines are not exclusionary) for receipt of any licensed vaccine through 28 days following the last dose of IP or any seasonal influenza vaccine within 14 days before the first dose of IP or plans for receipt of any seasonal influenza vaccine 14 days following the last dose of IP.
- Participated in an interventional clinical study, other than mRNA-1273-P203 study, within 28 days prior to the Screening Visit (BD-Day 0) or plans to do so while participating in this study.
-
History of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically:
- Congenital or acquired immunodeficiency, including human immunodeficiencyvirus (HIV) infection.
- Suspected active hepatitis
- Has a bleeding disorder that is considered a contraindication to IM injection orphlebotomy
- Dermatologic conditions that could affect local solicited AR assessments
- History of anaphylaxis, urticaria, or other significant AR requiring medicalintervention after receipt of a vaccine
- Diagnosis of malignancy within the previous 10 years (excluding nonmelanomaskin cancer)
- Febrile seizures
Part 1C-2 Heterologous Booster Dose:
- Has a known history of SARS-CoV-2 infection within 2 weeks prior to administration of IP or known close contact with anyone with laboratory-confirmed SARS-CoV-2 infection or COVID 19 within 2 weeks prior to administration of IP.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04649151
| Contact: Moderna Clinical Trials Support Center | 1-877-777-7187 | clinicaltrials@modernatx.com | |
| Contact: See "Additional Information" below to access study website |
Show 86 study locations
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | ModernaTX, Inc. |
| ClinicalTrials.gov Identifier: | NCT04649151 |
| Other Study ID Numbers: |
mRNA-1273-P203 |
| First Posted: | December 2, 2020 Key Record Dates |
| Last Update Posted: | May 19, 2023 |
| Last Verified: | May 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
COVID-19 COVID-19 Vaccine mRNA-1273 mRNA-1273 vaccine SARS-CoV-2 SARS-CoV-2 Vaccine mRNA-1273.222 vaccine SARS-CoV-2 VOC |
SARS-CoV-2 VOC vaccine Omicron Variant Coronavirus Virus Diseases Messenger RNA Moderna |